Skip to Content

Healius Ltd

HLS: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
A$6.00TwdWgghfndfh

Healius Earnings: Pathology Margins Weak but Set to Recover

No-moat Healius’ first-half fiscal 2024 group revenue and EBIT fell 2% and 61% to AUD 849 million and AUD 16 million, respectively. This was largely due to higher-margin coronavirus revenue falling 97% but was broadly in line with our expectations. As flagged, first-half group EBIT excluding coronavirus testing was flat on last year, weighed down by rent and wage inflation.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of HLS so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center